Quest Says It's Not Infringing Myriad's Gene Patents
Law360, Los Angeles (October 11, 2013, 4:36 PM EDT) -- Quest Diagnostics Inc. hit Myriad Genetics Inc. with a lawsuit in California federal court on Thursday, seeking a declaration that Quest does not directly or indirectly infringe a number of Myriad’s patents, including those protecting genes associated with an increased risk of breast cancer.
Quest says Myriad has threatened a patent infringement suit against any company that makes, uses, sells or offers to sell genetic tests and related services that use sequencing and analysis of BRCA1 and BRCA2 genes, which encode specific proteins responsible for repairing damaged DNA cells. BRCA1/BRCA2 screening assays identify particular harmful gene mutations, in DNA obtained from...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!